Latest Breaking News On - Nonclinical development - Page 1 : vimarsana.com

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesMadhoosudan patilSanjay nayakChintan patelPravinu dugelResearch developmentNonclinical developmentExchange commissionPanel titleAssociation for researchOcular therapeutix incAboutoculartherapeutix incSeattle convention centerCompany phaseTwo ophthalmology meetingsOphthalmology innovation source

TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

WALTHAM, Mass., April 22, 2024 TScan Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of T cell receptor -engineered T cell therapies for the treatment.

United statesMichelle matzkoShazad khokharCandace perulloHeather savelleHannah baderMaghan meyersAmerican society of geneTscan therapeutics incGlobe newswire tscan therapeutics incNonclinical developmentClinical developmentAmerican societyCell therapyAnnual meetingPresentation details

Alterity Therapeutics to Present New Data on ATH434 at the

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”),.

United statesSan franciscoRemy bernardaDanielo claassenMargaret bradburyDavid stamlerDaniel claassenHannah howlettDepartment of pharmaceutical sciencesNonclinical developmentEuropean commissionAlterity therapeuticsWorld orphan drug congress united statesAmerican academy of neurologyWayne state universityNational institute of health

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 Alterity Therapeutics , a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today.

United statesSan franciscoHannah howlettRemy bernardaMargaret bradburyDanielo claassenDavid stamlerDaniel claassenVanderbilt university medical centerSecurities exchangeParkinson foundationEuropean commissionSystem atrophy national institute of neurological disordersNonclinical developmentDepartment of pharmaceutical sciencesWorld orphan drug congress united states

IVIEW Announces Presentation of Positive Topline Results in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis at ARVO 2024

IVIEW Therapeutics Inc. announces to present the positive topline result in the Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial.

New jerseyUnited statesWeiyun shiFrancis mahRubo liangAssociation for researchView therapeutics incTherapeutics incEye hospital of shandong first medical universityNonclinical developmentBacterial conjunctivitisParallel controlled studyClinical efficacyPovidone iodineGel forming ophthalmic solution comparedOfloxacin eye drops